Lv1
20 积分 2025-11-25 加入
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2个月前
已完结
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
2个月前
已完结
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
3个月前
已完结
皖公网安备34019202002308
